memantine has been researched along with Acute Onset Vascular Dementia in 57 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine efficacy and safety of memantine for people with dementia." | 9.01 | Memantine for dementia. ( Debarros, J; Farrimond, LE; Maayan, N; McShane, R; Minakaran, N; Roberts, E; Schneider, L; Ware, J; Westby, MJ, 2019) |
| "Memantine, a low affinity antagonist to glutamate NMDA receptors, may prevent excitatory neurotoxicity in dementia." | 8.83 | Memantine for dementia. ( Areosa Sastre, A; McShane, R; Minakaran, N, 2006) |
| ":Memantine 20 mg/day caused a clinically noticeable reduction in deterioration over 28 weeks in patients with moderate to severe Alzheimer disease." | 8.82 | Memantine for dementia. ( Areosa Sastre, A; McShane, R; Sherriff, F, 2004) |
| "Double-blind, parallel group, placebo-controlled, randomized and unconfounded trials in which memantine was administered to people with dementia." | 8.82 | Memantine for dementia. ( Areosa, SA; Sherriff, F, 2003) |
| "Double-blind, parallel group, placebo-controlled, randomized and unconfounded trials in which memantine was administered to people with dementia." | 8.82 | Memantine for dementia. ( Areosa, SA; Sherriff, F, 2003) |
| "Memantine, a low affinity antagonist to glutamate NMDA receptors, may prevent excitatory neurotoxicity in dementia." | 8.82 | Memantine for dementia. ( Areosa, SA; McShane, R; Sherriff, F, 2005) |
| "Memantine, a low affinity antagonist to glutamate NMDA receptors, may prevent excitatory neurotoxicity in dementia." | 8.82 | Memantine for dementia. ( Areosa, SA; McShane, R; Sherriff, F, 2005) |
| "To determine efficacy and safety of memantine for people with dementia." | 5.01 | Memantine for dementia. ( Debarros, J; Farrimond, LE; Maayan, N; McShane, R; Minakaran, N; Roberts, E; Schneider, L; Ware, J; Westby, MJ, 2019) |
| "Memantine, a low affinity antagonist to glutamate NMDA receptors, may prevent excitatory neurotoxicity in dementia." | 4.83 | Memantine for dementia. ( Areosa Sastre, A; McShane, R; Minakaran, N, 2006) |
| "Memantine, a low affinity antagonist to glutamate NMDA receptors, may prevent excitatory neurotoxicity in dementia." | 4.82 | Memantine for dementia. ( Areosa, SA; McShane, R; Sherriff, F, 2005) |
| "Double-blind, parallel group, placebo-controlled, randomized and unconfounded trials in which memantine was administered to people with dementia." | 4.82 | Memantine for dementia. ( Areosa, SA; Sherriff, F, 2003) |
| "Double-blind, parallel group, placebo-controlled, randomized and unconfounded trials in which memantine was administered to people with dementia." | 4.82 | Memantine for dementia. ( Areosa, SA; Sherriff, F, 2003) |
| ":Memantine 20 mg/day caused a clinically noticeable reduction in deterioration over 28 weeks in patients with moderate to severe Alzheimer disease." | 4.82 | Memantine for dementia. ( Areosa Sastre, A; McShane, R; Sherriff, F, 2004) |
| "Memantine is a relatively new drug specially developed for use in moderate-to-severe dementia." | 4.82 | Memantine: pharmacological properties and clinical uses. ( Kumar, S, 2004) |
| "Memantine, a low affinity antagonist to glutamate NMDA receptors, may prevent excitatory neurotoxicity in dementia." | 4.82 | Memantine for dementia. ( Areosa, SA; McShane, R; Sherriff, F, 2005) |
| "Memantine is a uncompetitive, moderate affinity N-methyl-D-aspartate receptor antagonist." | 3.80 | A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). ( Möbius, HJ; Stöffler, A; Wilcock, G, 2002) |
| "All four dementia drugs available on the Swedish market (three cholinesterase inhibitors [donepezil, rivastigmine and galantamine] and memantine) were prescribed at the two dementia clinics." | 3.79 | Is drug treatment for dementia followed up in primary care? A Swedish study of dementia clinics and referring primary care centres. ( Johnell, K; Sonde, L, 2013) |
| "The cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog) was a primary endpoint in both trials, and in both trials a statistically significant difference was seen between treatment groups after 28 weeks." | 2.71 | Memantine in vascular dementia. ( Möbius, HJ; Stöffler, A, 2003) |
| " Memantine was well tolerated with a frequency of adverse events comparable to placebo." | 2.70 | Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). ( Forette, F; Möbius, HJ; Orgogozo, JM; Rigaud, AS; Stöffler, A, 2002) |
| "Although criteria for the diagnosis of vascular dementia (VaD) are established, the diagnostic concept is still controversial and there is no regulatory guidance for clinical drug development." | 2.70 | New approaches to clinical trials in vascular dementia: memantine in small vessel disease. ( Möbius, HJ; Stöffler, A, 2002) |
| "Vascular dementia is an umbrella term, encompassing the pathological changes in the brain due to cerebrovascular disease that result in dementia." | 2.53 | [How Treatable is Vascular Dementia?]. ( Mori, E, 2016) |
| "However, unlike stroke, treatment of hyperlipidemia with statin class drugs or treatment of blood clotting abnormalities with acetylsalicylic acid do not appear to have an effect on VaD incidence or progression." | 2.48 | Pharmacological prevention and treatment of vascular dementia: approaches and perspectives. ( Baskys, A; Cheng, JX, 2012) |
| "Today there is no causal therapy for Alzheimer's disease (AD)." | 2.45 | [Antidementia drugs]. ( Müller-Spahn, F; Sollberger, D; Wollmer, MA, 2009) |
| "Alzheimer's disease (AD) and Vascular dementia represent the most common forms of dementia." | 2.44 | Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation. ( Lipton, SA, 2007) |
| " Trial methods, clinical characteristics, outcomes, and adverse events were extracted and checked." | 2.44 | Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. ( Kavirajan, H; Schneider, LS, 2007) |
| "Memantine has been clinically used in the treatment of organic disorders in Germany for over ten years and has now been approved in Europe and also in the US for moderate to severe Alzheimer's disease." | 2.43 | Memantine: a therapeutic approach in treating Alzheimer's and vascular dementia. ( Fischer-Barnicol, D; Koch, HJ; Uyanik, G, 2005) |
| "Donepezil was shown to provide benefits in cognition, global function, and activities of daily living compared with placebo." | 2.43 | Use of antidementia agents in vascular dementia: beyond Alzheimer disease. ( Farlow, MR, 2006) |
| "Vascular dementia is the second cause of dementia after Alzheimer's disease." | 2.42 | [Diagnosis and treatment of vascular dementia]. ( Gold, G, 2004) |
| "Memantine has shown to be effective and safe in the treatment of dementia, particularly Alzheimer's disease, in controlled clinical trials." | 2.42 | NMDA-antagonism (memantine): an alternative pharmacological therapeutic principle in Alzheimer's and vascular dementia. ( Haen, E; Koch, HJ; Szecsey, A, 2004) |
| " This study investigated the effect of scalp electroacupuncture combined with Memantine in VaD." | 1.56 | The effect of scalp electroacupuncture combined with Memantine in patients with vascular dementia: A retrospective study. ( Gao, J; Han, X; Huang, L; Mao, E; Wu, G; Yue, A; Zhou, B, 2020) |
| " Demographic variables, quantity and rate of prescriptions, dosage forms and strengths were analyzed." | 1.39 | [Drugs used for cognitive impairment. Analysis of 1.5 million prescriptions in Argentina]. ( Arizaga, RL; Demey, I; Rojas, G, 2013) |
| "Donepezil 5 mg daily, donepezil 10 mg daily, galantamine 16-24 mg daily, rivastigmine flexible dosing up to 6 mg twice daily, or memantine 10 mg twice daily versus standard care." | 1.35 | Cost-effectiveness: cholinesterase inhibitors and memantine in vascular dementia. ( Anis, AH; Bansback, N; Lee, PE; Wong, CL, 2009) |
| "Memantine is a second-line option, as its adverse effects differ from those of anticholinesterases." | 1.32 | Memantine: new preparation. Poor evaluation and uncertain benefit in Alzheimer's disease. ( , 2003) |
| "The authors report 2 cases, in Alzheimer's disease and vascular dementia, in which erotomania emerged in the early stage of the underlying disorder." | 1.32 | Erotomania variants in dementia. ( Brüne, M; Schröder, SG, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (3.51) | 18.2507 |
| 2000's | 37 (64.91) | 29.6817 |
| 2010's | 15 (26.32) | 24.3611 |
| 2020's | 3 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Perlett, L | 3 |
| Smith, EE | 3 |
| Sun, Y | 2 |
| Wei, YJ | 1 |
| Xing, Y | 1 |
| Mak, S | 1 |
| Liu, Z | 2 |
| Wu, L | 1 |
| Guo, B | 1 |
| Luo, F | 1 |
| Hu, S | 1 |
| Wang, J | 1 |
| Cui, G | 1 |
| Wang, Y | 1 |
| Zhang, G | 1 |
| Han, Y | 1 |
| Zhang, Z | 1 |
| Yue, A | 1 |
| Han, X | 1 |
| Mao, E | 1 |
| Wu, G | 1 |
| Gao, J | 1 |
| Huang, L | 1 |
| Zhou, B | 1 |
| Blom, K | 1 |
| van den Elsen, GAH | 1 |
| Koek, HL | 1 |
| Sanders, JB | 1 |
| Kruithof, HC | 1 |
| Claassen, JAHR | 1 |
| Knight, R | 1 |
| Khondoker, M | 1 |
| Magill, N | 1 |
| Stewart, R | 1 |
| Landau, S | 1 |
| Hausner, L | 1 |
| Frölich, L | 1 |
| McShane, R | 5 |
| Westby, MJ | 1 |
| Roberts, E | 1 |
| Minakaran, N | 2 |
| Schneider, L | 1 |
| Farrimond, LE | 1 |
| Maayan, N | 1 |
| Ware, J | 1 |
| Debarros, J | 1 |
| Sonde, L | 1 |
| Johnell, K | 1 |
| Rodda, J | 1 |
| Carter, J | 1 |
| Rojas, G | 1 |
| Demey, I | 1 |
| Arizaga, RL | 1 |
| van de Glind, EM | 1 |
| van Enst, WA | 1 |
| van Munster, BC | 1 |
| Olde Rikkert, MG | 1 |
| Scheltens, P | 1 |
| Scholten, RJ | 1 |
| Hooft, L | 1 |
| Witter, D | 1 |
| McCord, M | 1 |
| Suryadevara, U | 1 |
| Mori, E | 1 |
| Iraqi, A | 1 |
| Hughes, TL | 1 |
| Müller-Spahn, F | 1 |
| Sollberger, D | 1 |
| Wollmer, MA | 1 |
| Wong, CL | 1 |
| Bansback, N | 1 |
| Lee, PE | 1 |
| Anis, AH | 1 |
| Peters, N | 1 |
| Dichgans, M | 1 |
| van den Bussche, H | 1 |
| Kaduszkiewicz, H | 1 |
| Koller, D | 1 |
| Eisele, M | 1 |
| Steinmann, S | 1 |
| Glaeske, G | 1 |
| Wiese, B | 1 |
| Olivares, D | 1 |
| Deshpande, VK | 1 |
| Shi, Y | 1 |
| Lahiri, DK | 1 |
| Greig, NH | 1 |
| Rogers, JT | 1 |
| Huang, X | 1 |
| Baskys, A | 1 |
| Cheng, JX | 1 |
| Wilcock, G | 2 |
| Möbius, HJ | 4 |
| Stöffler, A | 4 |
| Areosa, SA | 4 |
| Sherriff, F | 5 |
| Winblad, B | 2 |
| Kivipelto, M | 1 |
| Bonelli, RM | 1 |
| Fuchsberger, T | 1 |
| Möller, HJ | 2 |
| Hampel, H | 2 |
| Brüne, M | 1 |
| Schröder, SG | 1 |
| Findlay, DJ | 1 |
| Connelly, PJ | 1 |
| Koch, HJ | 2 |
| Szecsey, A | 1 |
| Haen, E | 1 |
| Bowler, JV | 1 |
| Gold, G | 1 |
| Kumar, S | 1 |
| Areosa Sastre, A | 2 |
| Román, GC | 1 |
| Rossom, R | 1 |
| Dysken, M | 1 |
| Padberg, F | 1 |
| Bottlender, R | 1 |
| Uyanik, G | 1 |
| Fischer-Barnicol, D | 1 |
| Martínez-Vila, E | 1 |
| Murie-Fernández, M | 1 |
| Gállego Pérez-Larraya, J | 1 |
| Irimia, P | 1 |
| Johannsen, P | 1 |
| Farlow, MR | 1 |
| Burns, A | 1 |
| O'Brien, J | 1 |
| Auriacombe, S | 1 |
| Ballard, C | 1 |
| Broich, K | 1 |
| Bullock, R | 1 |
| Feldman, H | 1 |
| Ford, G | 1 |
| Knapp, M | 1 |
| McCaddon, A | 1 |
| Iliffe, S | 1 |
| Jacova, C | 1 |
| Jones, R | 1 |
| Lennon, S | 1 |
| McKeith, I | 1 |
| Orgogozo, JM | 2 |
| Purandare, N | 1 |
| Richardson, M | 1 |
| Ritchie, C | 1 |
| Thomas, A | 1 |
| Warner, J | 1 |
| Wilkinson, D | 1 |
| Maggiore, C | 1 |
| Locatelli, L | 1 |
| Grandi, FC | 1 |
| Pizzolato, G | 1 |
| Birks, J | 1 |
| Flicker, L | 1 |
| Lipton, SA | 1 |
| Kavirajan, H | 1 |
| Schneider, LS | 1 |
| Nyenhuis, DL | 1 |
| Gorelick, PB | 1 |
| Poritis, N | 1 |
| Rigaud, AS | 1 |
| Forette, F | 1 |
| Ditzler, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective, Randomized, Multi-Center, Double-Blind, 26 Week, Placebo-Controlled Trial of Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia[NCT00545974] | Phase 4 | 81 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| Effects of Combined Memantine (Namenda) Plus Escitalopram (Lexapro) Treatment in Elderly Depressed Patients With Cognitive Impairment[NCT01876823] | Phase 2/Phase 3 | 60 participants (Actual) | Interventional | 2006-04-30 | Completed | ||
| A 24-Week Pilot, Double-Blind, Randomized, Parallel, Placebo-Controlled Study of Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:Correlation With Cognitive Evoked Potentials During Recovery.[NCT00196703] | Phase 4 | 30 participants | Interventional | 2005-03-31 | Recruiting | ||
| A 24-Week Pilot, Double-Blind, Randomized, Parallel, Placebo-Controlled Study of Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:Correlation With Cognitive Evoked Potentials During Recovery.[NCT00640198] | Phase 4 | 28 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
NPI:12-domain caregiver assessment of behavioral disturbances occurring in dementia: delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, motor disturbance, appetite/eating, nighttime behavior. A screening question is asked about each sub-domain. If the responses to these questions indicate that the patient has problems with a particular sub-domain of behavior, the caregiver is only then asked all the questions about that domain, rating the frequency of the symptoms on a 4-point scale, their severity on a 3-point scale, and the distress the symptom causes them on a 5-point scale. Severity(1=Mild to 3=Severe),frequency(1=occasionally to 4=very frequently) scales recorded for each domain; frequency*severity=each domain score(range 0-12). Total score=sum of each domain score(range 0-144);higher score=greater behavioral disturbances;negative change score from baseline=improvement. (NCT00545974)
Timeframe: Baseline, 26 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Memantine | -1.9 |
| Placebo | 0.3 |
The scale is rated on a 7-point scale, using a range of responses from 1 (very much improved) through 7 (very much worse). The clinician compares the participant's current condition to the condition at admission to the project. (NCT00545974)
Timeframe: 26 Weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Memantine | 4.4 |
| Placebo | 4.8 |
(NCT00545974)
Timeframe: 26 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Memantine | 1 |
| Placebo | 2 |
"Clinical dementia rating sum of boxes CDR-SB (0-18) high scores indicate high impairment.~Functional activities questionnaire FAQ (0-30) high scores indicate high impairment.~Texas functional living scale TFLS (0 to 52) high scores suggest better instrumental activities of daily living functioning.~Mini-Mental State Examination MMSE (0-30) low scores indicate low cognition. The executive interview EXIT25 (0 to 50) high scores indicate more executive impairment.~A modified unified Parkinson's disease rating scale UPDRS (0-199) high scores indicate worse disability.~Boston naming test (0-15) low scores indicate more retrieval difficulties." (NCT00545974)
Timeframe: Baseline and 26 Weeks
| Intervention | units on a scale (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| CDR-SB | FAQ | TFLS | MMSE | EXIT25 | UPDRS | Boston naming test | |
| Memantine | 1.5 | 4.3 | -3.7 | -1.2 | 1.9 | 1.7 | -1.4 |
| Placebo | 1.5 | 2.9 | -2.8 | -0.9 | 0.7 | 1.4 | 0.7 |
"Letter fluency, score is number of words recalled starting with a specified letter for 60 seconds. There are 3 trials, with 3 different letters. The total number of correct responses is totaled for all 3 trials for the score. Low scores indicate high impairment~Category fluency, score is number of items generated belonging to a specific category (such as animals) in 60 seconds, low scores indicate high impairment.~Digit symbol, score is number of symbols that correctly corresponded to the random numerals entered in the form in 90 seconds. Participants are given a table of numerals with matching symbols, and a form with random numerals with open spaces. Low scores indicate high impairment.~Digits backwards, score is number of digits backwards recalled (range: 0-14), The participant hears a list of digits and is asked to repeat the digits backwards. Low scores indicate high impairment." (NCT00545974)
Timeframe: Baseline and 26 Weeks
| Intervention | number of items recalled (Mean) | |||
|---|---|---|---|---|
| Letter fluency | Category fluency | Digit symbol | Digits backwards | |
| Memantine | -0.1 | -0.5 | -3.9 | 0.1 |
| Placebo | -0.3 | -0.7 | 4.2 | -0.2 |
Change in 24-item Hamilton Rating Scale for Depression (HAMD) scores from baseline to Week 48: HAMD measures depression severity based on a series of 24 items items. The range of HAMD total score is 0-74; 0 indicates no depressive symptoms and a maximum HAMD score is a 74, where the greater the score indicates more significant psychopathology. In this study, moderate to severe depression is considered a HAMD-24 greater than 14. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | scores on a scale (Mean) |
|---|---|
| Es-citalopram and Memantine Treatment | -15.2 |
Change in Selective Reminding Test-Delayed Recall scores from baseline to Week 48: SRT Delay is administered 15 minutes after the immediate recall portion. Patients are asked to remember as many of the words as they can from the 6 trials. Maximum raw score is a 12 for free recall. If a patient is unable to recall a word, they are given a chance to recognize it among three incorrect word choices. Maximum raw score for recognition is 12. The greater the score on the delayed recall portion, the better the patient does on the assessment. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | units on a scale (Mean) |
|---|---|
| Es-citalopram and Memantine Treatment | 1.2 |
Change in Selective Reminding Test-Total Immediate Recall (SRT-IR) scores from baseline to Week 48: Measures word recall (maximum 12 words per trial, across 6 trials). Maximum total recall score across 6 trials is 72; minimum recall is 0 across 6 trials. The higher the raw score, the better the patient did at recalling the target words. The unit of measure is the raw score, or the sum of the number of words recalled across all 6 trials. (NCT01876823)
Timeframe: baseline, 48 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Es-citalopram and Memantine Treatment | 7.5 |
Change in Trails A scores from baseline to Week 48: Measures attention and executive function. It asks patients to connect numbers from 1-25 in numerical order as fast as they can. Patients are timed; the longer it takes for the patient to connect the numbers, the worse their score. Unit of measure is in seconds. The amount of errors that the patient makes during trails is also recorded. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | seconds (Mean) |
|---|---|
| Es-citalopram and Memantine Treatment | 1.9 |
Change from baseline to Week 48 on Trails B: Measures attention and executive function. It asks patients to connect numbers and letters in numerical to alphabetical order from (1-13 and A-L) as fast as they can. Patients are timed; the longer it takes for the patient to connect the numbers and letters, the worse their score. Unit of measure is in seconds. The amount of errors that the patient makes during trails is also recorded. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | seconds (Mean) |
|---|---|
| Es-citalopram and Memantine Treatment | -36.3 |
Change in Wechsler Memory Scale-III scores from baseline to Week 48: The WMS-III Visual Reproduction sub-test was used to measure visual working memory and delayed memory. Patients were shown pictures of four drawings and were asked to reproduce them from memory immediately after seeing them, and 25 minutes after seeing them. The four scores are summed and the greater the total raw score, the better the patient did on the assessment. The maximum raw score for this test is a 41 on both the immediate and delayed portions (the overall range is 0-82 points). The change score is calculated using the total scores of both the immediate and delayed portions. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | units on a scale (Mean) |
|---|---|
| Es-citalopram and Memantine Treatment | 9.9 |
The CDR is a numeric rating scale that is used to quantify the severity of one's cognitive function. The scale goes from 0=normal; 0.5=mild cognitive impairment; 1 to 3=mild to moderate/severe dementia. CDR was used a dichotomous outcome measure (no=0; yes=1). (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | participants (Number) |
|---|---|
| Es-citalopram and Memantine Treatment | 1 |
The CGI Cognitive Change follows a seven-point likert scale. Compared to the patient's condition at baseline in the study [prior to medication initiation], the patient's condition is rated as: 1=very much improved since the initiation of treatment; 2=much improved; 3=minimally improved; 4=no change from baseline (the initiation of treatment); 5=minimally worse; 6= much worse; 7=very much worse since the initiation of treatment. Responses from the entire group were calculated. Mean at final visit and baseline is reported below. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | units on a scale (Mean) | |
|---|---|---|
| CGI-Cognitive Change (Baseline) | Clinical Global Impression-Cogntive Change (WK 48) | |
| Es-citalopram and Memantine Treatment | 3.6 | 2.7 |
The CGI Depression Change follows a seven-point likert scale. Compared to the patient's condition at baseline in the study [prior to medication initiation], the patient's condition is rated as: 1=very much improved since the initiation of treatment; 2=much improved; 3=minimally improved; 4=no change from baseline (the initiation of treatment); 5=minimally worse; 6= much worse; 7=very much worse since the initiation of treatment. Responses were calculated for the entire group. Mean at final visit has been reported below. Higher mean at baseline indicates a decrease in depression scores. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Cognitive Global Impression at Baseline | Cognitive Global Impression at Final Visit (WK 48) | |
| Es-citalopram and Memantine Treatment | 4.1 | 2.1 |
"Somatic side effect rating scale which includes 26 common somatic side effects associated with previous medication clinical trials; rated by the study physician. Factors were dichotomized to yes or no responses on this scale, which equated to the symptom being either present or not present. Yes and no responses were given a value of 0 (no) or 1 (yes). Responses from the entire group were calculated and the mean at baseline and the last visit is reported below." (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Treatment Emergent Side Effects (Baseline) | Treatment Emergent Side Effects (WK 48) | |
| Es-citalopram and Memantine Treatment | 6.6 | 3.2 |
33 reviews available for memantine and Acute Onset Vascular Dementia
| Article | Year |
|---|---|
Treatment of Vascular and Neurodegenerative Forms of Cognitive Impairment and Dementias.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cognitive Dysfunction; Dementia, Vascular; Humans; Memanti | 2023 |
Treatment of Vascular and Neurodegenerative Forms of Cognitive Impairment and Dementias.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cognitive Dysfunction; Dementia, Vascular; Humans; Memanti | 2023 |
Treatment of Vascular and Neurodegenerative Forms of Cognitive Impairment and Dementias.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cognitive Dysfunction; Dementia, Vascular; Humans; Memanti | 2023 |
Treatment of Vascular and Neurodegenerative Forms of Cognitive Impairment and Dementias.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cognitive Dysfunction; Dementia, Vascular; Humans; Memanti | 2023 |
Treatment of Vascular and Neurodegenerative Forms of Cognitive Impairment and Dementias.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cognitive Dysfunction; Dementia, Vascular; Humans; Memanti | 2023 |
Treatment of Vascular and Neurodegenerative Forms of Cognitive Impairment and Dementias.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cognitive Dysfunction; Dementia, Vascular; Humans; Memanti | 2023 |
Treatment of Vascular and Neurodegenerative Forms of Cognitive Impairment and Dementias.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cognitive Dysfunction; Dementia, Vascular; Humans; Memanti | 2023 |
Treatment of Vascular and Neurodegenerative Forms of Cognitive Impairment and Dementias.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cognitive Dysfunction; Dementia, Vascular; Humans; Memanti | 2023 |
Treatment of Vascular and Neurodegenerative Forms of Cognitive Impairment and Dementias.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cognitive Dysfunction; Dementia, Vascular; Humans; Memanti | 2023 |
[Treatment of dementia].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Dementia, Vascular; Humans; Memantine | 2017 |
A Systematic Review and Meta-Analysis of the Effectiveness of Acetylcholinesterase Inhibitors and Memantine in Treating the Cognitive Symptoms of Dementia.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Dementia, Vascular; Dopamine Agents; Humans | 2018 |
Memantine for dementia.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Akathisia, Drug-Induced; Alzheimer Disease; Cog | 2019 |
[Cholesterol inhibitor and memantine in symptomatic dementia therapy].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cooperative Behavior; Dementi | 2013 |
Pharmacological treatment of dementia: a scoping review of systematic reviews.
Topics: Aged; Aged, 80 and over; Behavior; Cholinesterase Inhibitors; Cognition Disorders; Data Interpretati | 2013 |
[How Treatable is Vascular Dementia?].
Topics: Cerebrovascular Disorders; Cholinesterase Inhibitors; Cognition Disorders; Dementia, Vascular; Human | 2016 |
[Antidementia drugs].
Topics: Aged; Alzheimer Disease; Amyloidosis; Cholinesterase Inhibitors; Dementia; Dementia, Vascular; Dose- | 2009 |
N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's disease.
Topics: Alzheimer Disease; Animals; Dementia, Vascular; Humans; Memantine; Neuroprotective Agents; Parkinson | 2012 |
Pharmacological prevention and treatment of vascular dementia: approaches and perspectives.
Topics: Alzheimer Disease; Antihypertensive Agents; Aspirin; Cholinesterase Inhibitors; Cognition; Dementia, | 2012 |
A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500).
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Cognition; Dementia, Vascular; Dizziness; Double-Blin | 2002 |
Memantine for dementia.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cognition Disorders; Dementi | 2003 |
Memantine offers new possibilities for the treatment of VaD.
Topics: Animals; Brain Ischemia; Clinical Trials as Topic; Cognition; Dementia, Vascular; Excitatory Amino A | 2002 |
Memantine for dementia.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cognition Disorders; Dementi | 2003 |
[Current therapy of patients with dementia].
Topics: Activities of Daily Living; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Controlled Cli | 2003 |
Memantine (Ebixa) in the later stages of dementia.
Topics: Antiparkinson Agents; Chronic Disease; Clinical Trials as Topic; Dementia; Dementia, Vascular; Human | 2003 |
NMDA-antagonism (memantine): an alternative pharmacological therapeutic principle in Alzheimer's and vascular dementia.
Topics: Alzheimer Disease; Clinical Trials as Topic; Dementia, Vascular; Dose-Response Relationship, Drug; D | 2004 |
[Diagnosis and treatment of vascular dementia].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antiparkinson Agents; Cholinesterase Inhibitors; Dementi | 2004 |
Memantine: pharmacological properties and clinical uses.
Topics: Alzheimer Disease; Cost-Benefit Analysis; Dementia; Dementia, Vascular; Excitatory Amino Acid Antago | 2004 |
Memantine for dementia.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cognition Disorders; Dementi | 2004 |
Memantine for dementia.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cognition Disorders; Dementi | 2005 |
Vascular dementia. Advances in nosology, diagnosis, treatment and prevention.
Topics: Biomarkers; Cholinesterase Inhibitors; Cognition Disorders; Dementia, Vascular; Humans; Hypertension | 2004 |
Efficacy and tolerability of memantine in the treatment of dementia.
Topics: Aged; Alzheimer Disease; Clinical Trials as Topic; Dementia, Vascular; Humans; Memantine; Receptors, | 2004 |
Memantine for dementia.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cognition Disorders; Dementi | 2005 |
Memantine: a therapeutic approach in treating Alzheimer's and vascular dementia.
Topics: Alzheimer Disease; Animals; Dementia, Vascular; Excitatory Amino Acid Antagonists; Glutamic Acid; Hu | 2005 |
Memantine for dementia.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cognition Disorders; Dementi | 2006 |
[Medical treatment of Alzheimer's disease].
Topics: Activities of Daily Living; Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; | 2006 |
Use of antidementia agents in vascular dementia: beyond Alzheimer disease.
Topics: Cholinesterase Inhibitors; Dementia, Vascular; Diagnosis, Differential; Donepezil; Dopamine Agents; | 2006 |
Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Combined Modality Therapy; Consensus Development | 2006 |
Investigational treatment for vascular cognitive impairment.
Topics: Cerebrovascular Disorders; Cholinesterase Inhibitors; Cognition Disorders; Dementia, Vascular; Drugs | 2007 |
Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation.
Topics: Adamantane; Alzheimer Disease; Animals; Dementia, Vascular; Humans; Memantine; Neuroprotective Agent | 2007 |
Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials.
Topics: Cholinesterase Inhibitors; Databases, Bibliographic; Dementia, Vascular; Donepezil; Dose-Response Re | 2007 |
Diagnosis and management of vascular cognitive impairment.
Topics: Central Nervous System Agents; Clinical Trials as Topic; Cognition Disorders; Dementia, Vascular; Do | 2007 |
6 trials available for memantine and Acute Onset Vascular Dementia
| Article | Year |
|---|---|
A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500).
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Cognition; Dementia, Vascular; Dizziness; Double-Blin | 2002 |
Memantine in vascular dementia.
Topics: Aged; Alzheimer Disease; Brain; Dementia, Vascular; Dopamine Agents; Humans; Magnetic Resonance Imag | 2003 |
Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine).
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Dementia, Vascular; Disabled Persons; Dopamine | 1999 |
New approaches to clinical trials in vascular dementia: memantine in small vessel disease.
Topics: Aged; Cognition; Dementia, Vascular; Double-Blind Method; Excitatory Amino Acid Antagonists; Humans; | 2002 |
Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).
Topics: Aged; Cognition; Dementia, Vascular; Disease Progression; Dizziness; Dopamine Agents; Double-Blind M | 2002 |
Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).
Topics: Aged; Cognition; Dementia, Vascular; Disease Progression; Dizziness; Dopamine Agents; Double-Blind M | 2002 |
Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).
Topics: Aged; Cognition; Dementia, Vascular; Disease Progression; Dizziness; Dopamine Agents; Double-Blind M | 2002 |
Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).
Topics: Aged; Cognition; Dementia, Vascular; Disease Progression; Dizziness; Dopamine Agents; Double-Blind M | 2002 |
Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).
Topics: Aged; Cognition; Dementia, Vascular; Disease Progression; Dizziness; Dopamine Agents; Double-Blind M | 2002 |
Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).
Topics: Aged; Cognition; Dementia, Vascular; Disease Progression; Dizziness; Dopamine Agents; Double-Blind M | 2002 |
Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).
Topics: Aged; Cognition; Dementia, Vascular; Disease Progression; Dizziness; Dopamine Agents; Double-Blind M | 2002 |
Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).
Topics: Aged; Cognition; Dementia, Vascular; Disease Progression; Dizziness; Dopamine Agents; Double-Blind M | 2002 |
Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).
Topics: Aged; Cognition; Dementia, Vascular; Disease Progression; Dizziness; Dopamine Agents; Double-Blind M | 2002 |
Efficacy and tolerability of memantine in patients with dementia syndrome. A double-blind, placebo controlled trial.
Topics: Aged; Aged, 80 and over; Dementia, Vascular; Double-Blind Method; Drug Therapy, Combination; Female; | 1991 |
19 other studies available for memantine and Acute Onset Vascular Dementia
| Article | Year |
|---|---|
Vascular cognitive impairment associated with NOTCH3 Exon 33 mutation: A case report.
Topics: Cognitive Dysfunction; Dementia, Vascular; Donepezil; Humans; Male; Memantine; Middle Aged; Mutation | 2019 |
Pharmacological Characterizations of anti-Dementia Memantine Nitrate via Neuroprotection and Vasodilation
Topics: Alzheimer Disease; Animals; Brain; Dementia, Vascular; Glutamic Acid; Memantine; Neurons; Neuroprote | 2020 |
The effect of scalp electroacupuncture combined with Memantine in patients with vascular dementia: A retrospective study.
Topics: Activities of Daily Living; Aged; Biomarkers; Cognition; Combined Modality Therapy; Dementia, Vascul | 2020 |
[Antidementia Drug Therapy of Alzheimer's Dementia: Status 2018 and Outlook].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Dementia, Vascular; Humans; Lewy Body Disease; Memanti | 2019 |
Is drug treatment for dementia followed up in primary care? A Swedish study of dementia clinics and referring primary care centres.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Dementia; Dementia, Vascular; Donepezil; Female; Galanta | 2013 |
[Drugs used for cognitive impairment. Analysis of 1.5 million prescriptions in Argentina].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Argentina; Child; Child, Preschool; Cholinesterase Inhib | 2013 |
Delirium Associated With Memantine Use in a Patient With Vascular Dementia.
Topics: Aged; Delirium; Dementia, Vascular; Excitatory Amino Acid Antagonists; Humans; Male; Memantine | 2015 |
Nightmares and memantine: a case report and review of literature.
Topics: Aged; Dementia, Vascular; Dopamine Agents; Dreams; Humans; Male; Memantine | 2009 |
Cost-effectiveness: cholinesterase inhibitors and memantine in vascular dementia.
Topics: Cholinesterase Inhibitors; Cost-Benefit Analysis; Dementia, Vascular; Dopamine Agents; Dose-Response | 2009 |
[Vascular dementia].
Topics: Aged; Brain; CADASIL; Cholinesterase Inhibitors; Cross-Sectional Studies; Dementia, Multi-Infarct; D | 2010 |
Antidementia drug prescription sources and patterns after the diagnosis of dementia in Germany: results of a claims data-based 1-year follow-up.
Topics: Age Factors; Aged; Aged, 80 and over; Alzheimer Disease; Ambulatory Care; Cholinesterase Inhibitors; | 2011 |
Editorial comment--How to treat vascular dementia?
Topics: Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Dementia, Vascular; Donepezil; Gala | 2003 |
Erotomania variants in dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Bipolar Disorder; Delusions; Dementia, Vascular; Dopamin | 2003 |
Vascular cognitive impairment.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Cerebrovascular Disorders; Cholinesterase Inhibito | 2004 |
Memantine: new preparation. Poor evaluation and uncertain benefit in Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Cost-Benefit Analysis; Demen | 2003 |
[Modern therapy for dementia].
Topics: Aged; Algorithms; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Comorbidity; De | 2005 |
Neuroprotection in vascular dementia.
Topics: Animals; Cholinesterase Inhibitors; Dementia, Vascular; Donepezil; Excitatory Amino Acid Antagonists | 2006 |
Memantine in the treatment of dementia.
Topics: Alzheimer Disease; Dementia; Dementia, Vascular; Excitatory Amino Acid Antagonists; Humans; Memantin | 2007 |
[Drug therapy of dementia. Improving cognitive performance].
Topics: Aged; Alzheimer Disease; Cognition Disorders; Dementia, Vascular; Humans; Memantine; Neuropsychologi | 2001 |